tbuckley/cabot-search huggingface dataset:
Association Between TTE Appropriateness, Echocardiographic Findings, and Clinical Outcomes
Authors: Tamryn K. Law, Zachary Bouck, X. Cindy Yin, David Dudzinski, Paaladinesh Thavendiranathan, Gillian C. Nesbitt, Jeremy Edwards, Kibar Yared, Harry Rakowski, Rory B. Weiner, R. Sacha Bhatia
Journal: JACC. Cardiovascular imaging (2018)
Diagnostic Concordance of Pathological Methods and Reports of Hematopathologists Compared to Local Nonspecialized Pathologists in the Diagnosis of Lymphoma in Mexico
Authors: Manuel Solano, Luis Arteaga, Ramon Martinez Hernandez, Alvaro Cabrero Garcia, David Gomez-Almaguer, Adrian Alejandro Ceballos Lopez, Oscar De Jesus Perez, Maria Carmen Lome Maldonado, Petra Yuridia Lizeth Alvarado Bernal, Alejandra Zárate Osorno, Mariana Fernandez, Paula Barreyro, Jose Alberto Regalado, Miguel Herrera-Rojas
Journal: Blood (2018)
Lead in Spices, Herbal Remedies, and Ceremonial Powders Sampled from Home Investigations for Children with Elevated Blood Lead Levels — North Carolina, 2011–2018
Authors: Kim A. Angelon-Gaetz, Christen Klaus, Ezan A. Chaudhry, Deidre K. Bean
Journal: MMWR Morbidity and Mortality Weekly Report (2018)

The number of pediatric cases of elevated blood lead levels (BLLs) are decreasing in North Carolina. However, one county reported an increase in the number of children with confirmed BLLs ≥5 μg/dL (CDC reference value, https://www.cdc.gov/nceh/lead/acclpp/blood_lead_levels.htm), from 27 in 2013 to 44 in 2017. Many children with elevated BLLs in this county lived in new housing, but samples of spices, herbal remedies, and ceremonial powders from their homes contained high levels of lead. Children with chronic lead exposure might suffer developmental delays and behavioral problems (https://www.cdc.gov/nceh/lead/). In 1978, lead was banned from house paint in the United States (1); however, children might consume spices and herbal remedies daily. To describe the problem of lead in spices, herbal remedies, and ceremonial powders, the North Carolina Childhood Lead Poisoning Prevention Program (NCCLPPP) retrospectively examined properties where spices, herbal remedies, and ceremonial powders were sampled that were investigated during January 2011-January 2018, in response to confirmed elevated BLLs among children. NCCLPPP identified 59 properties (6.0% of all 983 properties where home lead investigations had been conducted) that were investigated in response to elevated BLLs in 61 children. More than one fourth (28.8%) of the spices, herbal remedies, and ceremonial powders sampled from these homes contained ≥1 mg/kg lead. NCCLPPP developed a survey to measure child-specific consumption of these products and record product details for reporting to the Food and Drug Administration (FDA). Lead contamination of spices, herbal remedies, and ceremonial powders might represent an important route of childhood lead exposure, highlighting the need to increase product safety. Setting a national maximum allowable limit for lead in spices and herbal remedies might further reduce the risk for lead exposure from these substances.
Medical device industry: international investigation exposes lax regulation
Authors: Jeanne Lenzer
Journal: BMJ (2018)

The results of an international investigation tracking the harms of medical devices that have been tested inadequately or not at all are being released today. The investigation, called the Implant Files, was led by the Pulitzer prize winning International Consortium of Investigative Journalists (ICIJ) and conducted by 252 journalists from 36 countries representing 59 media partners, including The BMJ and UK partners BBC and the Guardian .

The investigation was inspired by a Dutch investigative journalist and broadcaster, Jet Schouten, who led a sting operation by convincing the private companies called notified bodies that are responsible for assessing devices that mesh netting from a bag of mandarin oranges was surgical mesh. Schouten said that the results made her want an investigation into device approval around the world.

Over the course of …
KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance
Authors: Kunihiko Hinohara, Hua-Jun Wu, Sébastien Vigneau, Thomas O. McDonald, Kyomi J. Igarashi, Kimiyo N. Yamamoto, Thomas Madsen, Anne Fassl, Shawn B. Egri, Malvina Papanastasiou, Lina Ding, Guillermo Peluffo, Ofir Cohen, Stephen C. Kales, Madhu Lal-Nag, Ganesha Rai, David J. Maloney, Ajit Jadhav, Anton Simeonov, Nikhil Wagle, Myles Brown, Alexander Meissner, Piotr Sicinski, Jacob D. Jaffe, Rinath Jeselsohn, Alexander A. Gimelbrant, Franziska Michor, Kornelia Polyak
Journal: Cancer Cell (2018)
Inconsistent Reporting of Potential Conflicts of Interest in <i>JAMA</i>
Authors: Mark B. McClellan
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Apatinib plus S-1 as second-line or later line treatment for advanced squamous cell lung carcinoma
Authors: Q. Shi, L. Xia, J. Zhou, Z. Wang, L. Sheng, G. Wang, L. Wang, X. Cheng, F. Wang, F. Kong, F. Zhao, X. Li, B. Ye, L. Mei, Y. Liu, L. Pan, J. Xie, G. Cheng, X. Li
Journal: Annals of Oncology (2018)
Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: A Large Real-Time Multi-Center Prospective Longitudinal Observational Study
Authors: Mohamed L. Sorror, Barry E. Storer, Aaron T. Gerds, Bruno C. Medeiros, Paul J Shami, John P. Galvin, Kehinde U. Adekola, Selina Luger, Maria R. Baer, David A. Rizzieri, Tanya M. Wildes, Eunice S. Wang, Stefan Faderl, Jamie L. Koprivnikar, Mikkael A. Sekeres, Sudipto Mukherjee, Julie Smith, Mitchell Garrison, Kiarash Kojouri, Jennifer E. Nyland, Rachelle R. Moore, Sophie L. Fleuret, Ylinne Lynch, Pamela S. Becker, Mary-Elizabeth M. Percival, Brenda M. Sandmaier, Frederick R. Appelbaum, Elihu H. Estey
Journal: Blood (2018)
The conduit system exports locally secreted IgM from lymph nodes
Authors: Guilhem R. Thierry, Mirela Kuka, Marco De Giovanni, Isabelle Mondor, Nicolas Brouilly, Matteo Iannacone, Marc Bajénoff
Journal: The Journal of Experimental Medicine (2018)

Immunoglobulin M (IgM) is the first type of antibody produced during acute infections and thus provides an early line of specific defense against pathogens. Being produced in secondary lymphoid organs, IgM must rapidly be exported to the blood circulation. However, it is currently unknown how such large pentameric molecules are released from lymph nodes (LNs). Here, we show that upon immunization, IgM transiently gains access to the luminal side of the conduit system, a reticular infrastructure enabling fast delivery of tissue-derived soluble substances to the LN parenchyma. Using microinjections of purified IgM, we demonstrate that conduit-associated IgM is delivered by neither the afferent lymph nor the blood, but is locally conveyed by conduits. Exploiting in vivo models, we further demonstrate that conduit-associated IgM is locally and transiently produced by activated, antigen-specific B cells migrating in the T cell zone. Thus, our study reveals that the conduit system is coopted by B cells to rapidly export secreted IgM out of LNs.
Clinical Responses to CAR.CD30-T Cells in Patients with CD30+ Lymphomas Relapsed after Multiple Treatments Including Brentuximab Vedotin
Authors: Natalie S Grover, Steven I Park, Anastasia Ivanova, Paul Eldridge, Kathryn McKay, Catherine Joyce Arago Cheng, Spencer Laing, Deborah Covington, John West, S. Elizabeth Sharf, J. Kaitlin Morrison, Shaw Scott, Erin Crecelius, Desirae Shelley, Maurice Alexander, Faith Brianne Buchanan, Emily Herrick Kassam, Megan McElfresh, Alicia R Pinto, Angela Denise Spruill, Ashley Zanter, Kimberly Wehner, Christopher Dittus, Thomas C. Shea, Gianpietro Dotti, Jonathan S Serody, Anne Beaven, Barbara Savoldo
Journal: Blood (2018)
The application of nitric oxide delivery in nanoparticle-based tumor targeting drug delivery and treatment
Authors: Lin Qin, Huile Gao
Journal: Asian Journal of Pharmaceutical Sciences (2018)

Nitric oxide (NO) shows great role in tumor biology. Recent years, more and more researches utilized NO donor in tumor targeting drug delivery and treatment. In this review, we summarized the NO donors by their endogenous and exogenous stimuli. Then the application of NO donors, which was the main aim of the review, was discussed in detailed according to their functions, including inducing tumor cell apoptosis, reversing tumor multidrug resistance, inhibiting tumor metastasis and improving drug delivery.
Abstract 9359: Effects of Pre-Hospital ECG Use and Patient Residence Distance From PCI Center on Time to Device Activation in ST Segment Elevation Myocardial Infarction: A Retrospective Analysis From the NCDR
Authors: Bryn E Mumma, Michael C Kontos, S A Peng, Deborah B Diercks
Journal: Circulation (2013)

Objective: American Heart Association guidelines recommend &lt;90 minutes from first medical contact (FMC) to reperfusion for ST segment elevation myocardial infarction (STEMI) patients. Prehospital electrocardiograms (ECGs) reduce time to reperfusion, but the relative influence of patient distance from a percutaneous coronary intervention (PCI) center on this effect is unclear. We evaluated the relationship between patient distance from a PCI center, prehospital ECG use, and interval from FMC to device activation among patients with STEMI. Methods: We performed a retrospective cohort study including all STEMI patients in the ACTION Registry-Get With the Guidelines from 7/1/2008 to 9/30/2012 who were transported by ground emergency medical services (EMS) to a PCI center. Patient distance was defined as the driving distance from the patient’s home zip code to the PCI center address as calculated by Google Maps. Home zip code was used as a surrogate for EMS call location. Patient distance was classified into tertiles (16.3 mi), and simple linear regression was used to characterize the interaction between prehospital ECG use and patient distance with respect to time to device activation. Results: Of the 29,506 STEMI patients, 19,690 (67%) received a prehospital ECG. The median patient distance to PCI center was 11.0 mi among patients with a prehospital ECG and 9.9 mi among those without. Overall, a prehospital ECG reduced the FMC to device activation time by 10.9 minutes (p&lt;0.001). This reduction in time from FMC to device was consistent across tertiles of distance (1st, median 11 minutes; 2nd, median 11 minutes; 3rd, median 10 minutes). The effect of prehospital ECG is attenuated by 0.8 minutes for every 10 mile increases in distance (interaction p=.0002). During off hours, median time from FMC to device activation was longer in each distance tertile when compared to work hours (86 vs 68, 86 vs 70, and 92 vs 77 minutes, respectively; p&lt;0.001 for all). Conclusion: Prehospital ECGs are commonly used among STEMI patients and reduce the time from FMC to device activation by approximately 10 minutes. Patient distance from a PCI center was not associated with this time interval, but presentation during off hours was associated with longer times.
External Validation and Revision of Thrombosis Lymphoma /Throly/ Score
Authors: Darko Antic, Natasa Milic, Biljana Mihaljevic, Bruce Cheson, Mayur Narkhede, Hikmat Abdel-Razeq, Irina Panovska, Sanja Trajkova, Marija Popova, Igor Aurer, Ana Boban, Michele Ghielmini, Alden Moccia, Aurelien Delluc, Jean-Christophe Ianotto, Ulrich Jaeger, Cathrin Skrabs, Grigorios T. Gerotziafas, Jawed Fareed
Journal: Blood (2018)
Making It Easier for Hospitals to Participate in, and Succeed Under, Bundled Payments
Authors: Daniel M. Blumenthal
Journal: JAMA Internal Medicine (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function
Authors: Sarah L. Buchan, Lang Dou, Marcus Remer, Steven G. Booth, Stuart N. Dunn, Chester Lai, Monika Semmrich, Ingrid Teige, Linda Mårtensson, Christine A. Penfold, H.T. Claude Chan, Jane E. Willoughby, C. Ian Mockridge, Lekh N. Dahal, Kirstie L.S. Cleary, Sonya James, Anne Rogel, Päivi Kannisto, Mats Jernetz, Emily L. Williams, Eugene Healy, J. Sjef Verbeek, Peter W.M. Johnson, Björn Frendéus, Mark S. Cragg, Martin J. Glennie, Juliet C. Gray, Aymen Al-Shamkhani, Stephen A. Beers
Journal: Immunity (2018)
Association of Blood Pressure Trajectories in Early Life with Subclinical Renal Damage in Middle Age
Authors: Wenling Zheng, Jianjun Mu, Chao Chu, Jiawen Hu, Yu Yan, Qiong Ma, Yongbo Lv, Xianjing Xu, Keke Wang, Yang Wang, Ying Deng, Bo Yan, Ruihai Yang, Jun Yang, Yong Ren, Zuyi Yuan
Journal: Journal of the American Society of Nephrology (2018)

Background Although high BP is one of the most important factors affecting renal function, whether longitudinal BP trajectories in early life course are associated with renal function damage in later life is unclear. Methods To investigate the correlation between BP trajectories from childhood to adulthood and renal function in middle age, we used group-based trajectory models to identify BP trajectories in 2430 individuals (aged 6–15 years old at baseline) participating in the ongoing Hanzhong Adolescent Hypertension Cohort. We tested the association between these trajectories and subclinical renal damage in middle age, adjusting for several covariates. Results We identified four distinct systolic BP trajectories among 2430 subjects: low stable, moderate stable, high stable, and moderate increasing on the basis of systolic BP levels at baseline and during the 30-year follow-up period. The urinary albumin-to-creatinine ratio (uACR) was higher in moderate stable, high stable, and moderate increasing groups compared with the low stable group. A total of 228 individuals had subclinical renal disease by 2017. Compared with the low stable trajectory group, the other groups had increasingly greater odds of experiencing subclinical renal disease in middle age. These associations were not altered after adjustment for other covariates, except for in the moderate stable group. Analyzed results were similar for the mean arterial pressure and diastolic BP trajectory groups. Conclusions Higher BP trajectories were correlated with higher of uACR levels and risk of subclinical renal disease in middle age. Identifying long-term BP trajectories from early age may assist in predicting individuals’ renal function in later life.
Lactate inhibits ATP6V0d2 expression in tumor-associated macrophages to promote HIF-2α–mediated tumor progression
Authors: Na Liu, Jing Luo, Dong Kuang, Sanpeng Xu, Yaqi Duan, Yu Xia, Zhengping Wei, Xiuxiu Xie, Bingjiao Yin, Fang Chen, Shunqun Luo, Huicheng Liu, Jing Wang, Kan Jiang, Feili Gong, Zhao-hui Tang, Xiang Cheng, Huabin Li, Zhuoya Li, Arian Laurence, Guoping Wang, Xiang-Ping Yang
Journal: Journal of Clinical Investigation (2018)

Macrophages perform key functions in tissue homeostasis that are influenced by the local tissue environment. Within the tumor microenvironment, tumor-associated macrophages can be altered to acquire properties that enhance tumor growth. Here, we found that lactate, a metabolite found in high concentration within the anaerobic tumor environment, activated mTORC1 that subsequently suppressed TFEB-mediated expression of the macrophage-specific vacuolar ATPase subunit ATP6V0d2. Atp6v0d2-/- mice were more susceptible to tumor growth, with enhanced HIF-2α-mediated VEGF production in macrophages that display a more protumoral phenotype. We found that ATP6V0d2 targeted HIF-2α but not HIF-1α for lysosome-mediated degradation. Blockade of HIF-2α transcriptional activity reversed the susceptibility of Atp6v0d2-/- mice to tumor development. Furthermore, in a cohort of patients with lung adenocarcinoma, expression of ATP6V0d2 and HIF-2α was positively and negatively correlated with survival, respectively, suggesting a critical role of the macrophage lactate/ATP6V0d2/HIF-2α axis in maintaining tumor growth in human patients. Together, our results highlight the ability of tumor cells to modify the function of tumor-infiltrating macrophages to optimize the microenvironment for tumor growth.
Unusual endoscopic treatment of recurrent cough and pneumonia
Authors: Jan Patrick Huber, Julia Lang, Robert Thimme, Arthur Schmidt, Dominik Bettinger
Journal: Gut (2018)

A 51-year-old male patient presented to our emergency department with fever, aggravating coughing and orthopnoea. Clinical evaluation revealed pneumonia in the right lower lobe of the lung and due to typical radiological hallmarks, aspiration pneumonia was suspected. During the last months, he had suffered from several pneumonias. The patient’s history showed that he suffered from alveolar soft tissue sarcoma which was first diagnosed in 1985. He was treated with right-sided hemihepatectomy for resection of liver metastases, further liver resections, 12 sessions of radiation therapy and seven transarterial chemoembolisation sessions. Moreover, the patient developed a stenosis of the left hepatic bile duct and required repeated biliary stenting (10F stent) by endoscopic retrograde cholangiopancreaticography (ERCP; …
Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria
Authors: Michael D. Tharp, Jonathan A. Bernstein, Abhishek Kavati, Benjamin Ortiz, Karen MacDonald, Kris Denhaerynck, Ivo Abraham, Christopher S. Lee
Journal: JAMA Dermatology (2018)

<h3>Importance</h3> Omalizumab is indicated for the management of chronic idiopathic urticaria (CIU) (also known as chronic spontaneous urticaria) in adolescents and adults with persistent hives not controlled with antihistamines. The effectiveness of omalizumab in the real-world management of CIU is largely unknown. <h3>Objective</h3> To quantitatively synthesize what is known about the benefits and harms of omalizumab in the real-world clinical management of CIU regarding urticaria activity, treatment response, and adverse events. <h3>Data Sources</h3> Published observational studies (January 1, 2006, to January 1, 2018) and scientific abstracts on the effectiveness of omalizumab in CIU were identified using PubMed, Embase, Web of Science, and Cochrane search engines; references were searched to identify additional studies. <h3>Study Selection</h3> Included studies were observational in design and included at least 1 outcome in common with other studies and at a concurrent time point of exposure to omalizumab. A total of 67 articles (35.2% of those screened) were included in the analysis. <h3>Data Extraction and Synthesis</h3> PRISMA and MOOSE guidelines were followed; independent selection and data extraction were completed by 2 observers. Random-effects meta-analyses were performed. <h3>Main Outcomes and Measures</h3> Main outcomes were change in weekly Urticaria Activity Score (UAS7; range, 0-42), change in Urticaria Activity Score (UAS; range 0-6) (higher score indicating worse outcome in both scales), complete and partial response rates (percentages), and adverse event rate (percentage). <h3>Results</h3> Omalizumab therapy was associated with an improvement in UAS7 scores (−25.6 points, 95% CI, −28.2 to −23.0;<i>P</i> &lt; .001; 15 studies, 294 patients), an improvement in UAS scores (−4.7 points, 95% CI, −5.0 to −4.4,<i>P</i> &lt; .001; 10 studies, 1158 patients), an average complete response rate of 72.2% (95% CI, 66.1%-78.3%;<i>P</i> &lt; .001; 45 studies, 1158 patients) with an additional average partial response rate of 17.8% (95% CI, 11.7%-23.9%;<i>P</i> &lt; .001; 37 studies, 908 patients), and an average adverse event rate of 4.0% (95% CI, 1.0%-7.0%;<i>P</i> &lt; .001; any level of severity, 47 studies, 1314 patients). <h3>Conclusions and Relevance</h3> Benefits and safety of omalizumab in the real-world treatment of CIU meet or exceed results gleaned from clinical trials. These real-world data on omalizumab in CIU may help inform both clinical treatment expectations and policy decision making.